Sai Life Sciences Limited has scheduled meetings with analysts and investors for August 13 and 14, 2026, in Singapore. The company will participate in the Avendus Spark INDX-Asia Edition 2026 event, engaging stakeholders through both one-on-one and group discussions to provide updates on its business operations and strategic direction.

The disclosure was made in compliance with Regulations 30 read with Schedule III of the SEBI (Listing Obligations and Disclosures Requirements) Regulations 2015. The company notified the Bombay Stock Exchange (BSE) and the National Stock Exchange of India (NSE) on August 04, 2026, regarding the upcoming engagement schedule.

Meeting Details

The interactions are structured to allow detailed dialogue between the company’s management and market participants. The format includes both individual consultations and broader group sessions, facilitating comprehensive coverage of investor queries.

Regulatory Compliance and Disclosure Policy

Runa Karan, Company Secretary and Compliance Officer of Sai Life Sciences Limited, signed the intimation letter submitted to the exchanges. The filing explicitly states that the company does not intend to discuss any unpublished price-sensitive information (UPSI) during these meetings. Furthermore, no new presentation materials will be distributed or presented during the sessions.

The schedule is subject to change due to exigencies on the part of the analysts, investors, or the company. Investors are advised to monitor official communications for any updates regarding timing or format adjustments. The meetings aim to maintain transparency and regular communication with the investment community without disclosing material non-public information.

Sai Life Sciences Limited will host an earnings conference call on Friday, August 7, 2026, at 4:00 PM IST to discuss its unaudited financial results for the quarter ended June 30, 2026. The announcement, filed with the National Stock Exchange of India Limited and BSE Limited on July 30, 2026, provides investors with the schedule to access management commentary on the company’s performance in Q1FY27. This disclosure ensures timely transparency regarding the firm's operational and financial standing for the period.

The conference call is conducted pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The session will begin with a brief management discussion on earnings performance, followed by an interactive question-and-answer segment. Investors and analysts can participate via dial-in or through a pre-registration link provided in the exchange filing.

Conference Call Details

Management Representation

Senior leadership from Sai Life Sciences Limited will address stakeholders during the call. The key participants include:

• Krishna Kanumuri, Managing Director & Chief Executive Officer
• Siva Chittor, Director and Chief Financial Officer

About Sai Life Sciences Limited

Sai Life Sciences is one of India's fastest-growing Contract Research, Development, and Manufacturing Organizations (CRDMO). Headquartered in Hyderabad, the company partners with innovator pharmaceutical and biotech firms to accelerate the discovery, development, and commercialization of new medicines. Its integrated solutions span medicinal chemistry, process development, clinical and commercial manufacturing, and advanced technology platforms.